INOVIO plans public offering of common stock and warrants to raise capital.

INOVIO Pharmaceuticals announced its intention to conduct an underwritten public offering of common stock along with Series A and Series B warrants. The company aims to raise capital to support its biotechnology efforts in developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. Piper Sandler is managing the offering, which includes a 30-day option for the underwriter to purchase additional securities. The offering is subject to market conditions and regulatory approvals, with further details to be filed with the SEC.